Honored to be a part of this amazing #IFNLambda expert group brought together by @prokuninaolsson to bring awareness to using IFN-lambda 1 in #COVID19 patients! Through zoom and online editing we were able to quickly put this together for @JExpMeddoi.org/10.1084/jem.20…
We discuss the major benefit IFNL1 may provide vs type I IFNs in #COVID19 or future emerging viruses with potentially less side effects/inflammation, but also discuss potential risks when we need more data specifically in humans which is a focus of my projects in the lab.
We are happy to see #Eiger will support IFNL1 clinical trials starting in the near future when patients desperately need new treatments but we recommend starting in patients with less serious disease or healthcare workers
• • •
Missing some Tweet in this thread? You can try to
force a refresh
I'm excited to make it #TwitterOfficial that I will be joining the Dept of Immunology at the University of Manitoba as an Assistant Professor and GSK Research Chair in Immunology of Infectious Diseases as of Nov 1, 2020!! @UM_Immu@UM_RadyFHS@umanitoba#newPI 1/5
I am so grateful to have this opportunity especially in these tough times. Thanks to all my mentors & colleagues over the yrs (most are not on Twitter). 2 undergrad summers with @NRC_CNRC & an amazing 5yrs at @UW Immunology with mentor Dr. Keith Elkon before back to 🇨🇦 2/5
Thank you to Dr. Michael Houghton & Dr. Lorne Tyrrell @LKSIoV for your mentorship & allowing me to build my own research program that I am excited to bring to @umanitoba where many new collaborations are possible. Thanks to everyone @UAlberta_MMI who helped along the way! 3/5
Thank you Dr. Marco Cassatella for highlighting our @PLOSPathogens article in @Facultyopinions ! The recommendation nicely sums up our findings about IFNLR exp on specific human immune cells & soluble IFNLR1 (only in primates) inhibiting responses doi.org/10.1371/journa… 1/4
Cassatella M: Faculty Opinions Recommendation of [Santer DM et al., PLoS Pathog 2020 16(4):e1008515]. In Faculty Opinions, 27 Aug 2020; 10.3410/f.737851343.793577620 2/4
The lack of responsiveness to IFNLs and lack of IFNLR1 expression on human neutrophils was also shown by @rishirajgoel et al. doi:10.1073/pnas.1916897117 by scRNA seq and other scRNA seq datasets show low to no IFNLR1 mRNA in human neutrophils... 3/4
Super excited and thankful to @CIHR_IRSC 🍁 for supporting our project to characterize IFN-lambda1 as a treatment for #COVID19 - our amazing team includes Lorne Tyrrell and myself @UAlberta_FoMD, and @JJFeld and Adam Gehring @UHN The clinical trial has already started... 1/3
To be ranked #1/339 was an extra bonus after working late nights to put this together in under 2 weeks! I know we will learn a lot about #COVID19, but also how IFN-lambda 1 modulates our immune system which has implications for potentially using IFNL1 against other viruses! 2/3
If you or someone you know in the Toronto area was recently diagnosed to be #SARSCoV2 positive, then @JJFeld is still enrolling patients for the trial 3/3 😀